MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.51
-0.50
-1.02%
After Hours: 48.51 0 0.00% 17:01 04/03 EDT
OPEN
48.15
PREV CLOSE
49.01
HIGH
49.64
LOW
47.95
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
86.58
52 WEEK LOW
39.32
MARKET CAP
6.75B
P/E (TTM)
23.52
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IONS stock price target is 67.94 with a high estimate of 120.00 and a low estimate of 19.00.

EPS

IONS News

More
  • The Top 10 Biotechnology Companies
  • Investopedia · 03/26 19:53
  • Hedge Funds Arent Done Buying Ionis Pharmaceuticals, Inc. (IONS)
  • Insider Monkey · 03/23 05:53
  • Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program
  • CNW Group · 03/13 12:00
  • The Dow Jones Industrial Average Just Had Its Worst Day Since 1987. Yes, You Can Call It Panic.
  • Barrons.com · 03/12 22:46

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About IONS

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
More

Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.